UBS raised its price target on Viatris to $20 from $18 and maintained a Buy rating after the company reported meeting its Q4 cost-savings objectives and issuing FY26 guidance above consensus. The analyst highlighted potential for mid-single-digit revenue growth and teen-level EPS CAGR, supporting valuation expansion over time.

Viatris reported Q4 2025 revenue of $14.3 billion and adjusted EBITDA of $4.2 billion, with CEO Scott Smith describing 2025 as a strong year that positioned the company for sustainable growth beginning in 2026. The company returned over $1 billion to shareholders through dividends and share repurchases and completed 60 regional transactions, including the acquisition of Aculys Pharma in Japan.

Viatris highlighted five Phase III studies that delivered positive results, marking a milestone in its development pipeline, and expects enrollment in key programs like cenerimod and selatogrel to complete in 2026. Management outlined a $650 million three-year cost-savings plan—with $250 million earmarked for reinvestment—and prepared operational redundancies for a potential FDA reinspection of its Indore facility.